In this regard, it was demonstrated that serum TGFβ levels increased in response to conventional IBD treatments, suggesting that upregulation of TGFβ is necessary to attenuate intestinal inflammation in IBD patients [49,50]. The gene discussed is TGFB1; the disease is inflammatory bowel disease.